Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Allergan Is Bullish on Biotech

by | Sep 22, 2016 5:14 pm | Biotechnology, Pharmaceuticals

Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced nine transactions for a total of $1.67 billion, more than Pfizer’s (NYSE: PFE) seven deals but far behind the $19.8 billion Pfizer committed to those transactions. (Pfizer’s biggest deal this year, the $13.5 billion acquisition of Medivation (NASDAQ: MDVN), was announced in August.)... Read More »

Allergan Adds Tobira to Its GI Pipeline

by | Sep 20, 2016 6:36 pm | Biotechnology, Pharmaceuticals

Allergan plc (NYSE: AGN) shows no signs of slowing its acquisition pace this year, and just solidified its lead in therapeutics for nonalcoholic steatohepatitis (NASH), an incurable disease affecting approximately 5% of the U.S. population. The pharma giant announced its acquisition of Tobira Therapeutics Inc. (NASDAQ: TBRA), This transaction marks the company’s eighth in 2016, and $1.63 billion spent in upfront payments alone since January. Tobira came with an upfront purchase price of $533.6 million, or $28.35 per share, and up to $49.84 per share in Contingent Value Rights that may be payable based on the successful completion of certain milestones, for a total consideration of up to... Read More »

Horizon Pharma Buys Raptor

by | Sep 16, 2016 8:31 am | Pharmaceuticals

For the week ending September 16, 2016, a combined $1.01 billion was spent on three pharmaceutical deals, one of which is also the largest pharmaceutical deal so far in September. Horizon Pharma plc (NASDAQ: HZNP), which develops, acquires and commercializes medicines for the treatment of arthritis, pain, inflammatory and/or orphan diseases, acquired Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) for approximately $800 million, or $9.00 per share. Raptor focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The transaction gives Horizon global rights to PROCYSBI® delayed-release capsules, used to treat nephropathic... Read More »

Stryker’s Minimally Invasive Acquisitions

by | Sep 15, 2016 6:28 pm | Medical Devices, Private Equity

For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million. Halfway through September, the company has made two more acquisitions, for undisclosed prices. For those keeping score, that’s eight deals for approximately $4.1 billion. Stryker’s most recent deals have targeted Ivy Sports Medicine, LLC for its minimally invasive meniscal repair platform, and Restore... Read More »

Allergan Eyes Clinical-Stage Ocular Drugs

by | Sep 14, 2016 8:45 am | Biotechnology, Pharmaceuticals

Allergan plc (NYSE: AGN) just purchased privately-held RetroSense Therapeutics LLC for $60 million in an all-cash transaction, with potential regulatory and commercialization milestone payments. Based in Ann Arbor Michigan, RetroSense is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in those suffering from blindness. Its lead development program, RST-001, is a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP). The acquisition gives Allergan global rights to RetroSense’s lead product candidate, RST-001. In 2014, RST-001 received Orphan Drug Designation by the U.S. FDA for the treatment of Retinitis... Read More »

Fresensius Helios Adds 43 Spanish Hospitals

by | Sep 13, 2016 8:04 am | Hospitals, Private Equity

Fresenius Helios (EXTRA: FRE.DE) was already the largest private hospital company in Europe, and now it’s grown even larger. On September 5, 2016, the company announced the acquisition of Quirónsalud, Spain’s largest private hospital operator, with 43 hospitals, 39 outpatient centers, and 300 occupational risk prevention centers.  Quirónsalud was created by the 2014 merger of IDC Salud and Grupo Hospitalario Quirón. Fresenius Helios, a division of Fresenius SE & Co. KGaA, vaulted to the top of the private European hospital market in September 2013, following the  its acquisition of 43 hospitals and 15 outpatient facilities in Germany, sold by Rhön Klinikum AG, for... Read More »

Stryker Corp. Makes Seventh Acquisition in 2016

by | Sep 9, 2016 3:23 pm | Medical Devices

Mergers and acquisitions in the medical device segment has been a bit sluggish this year. Even with two deals announced on September 1, marking 79th and 80th sector transactions in 2016, there is a lot of ground to make up to match the 114 deals announced in 2015. Stryker Corporation (NYSE: SYK) announced its seventh acquisition this year, paying an undisclosed amount for Ivy Sports Medicine, LLC. Ivy Sports Medicine provides medicine therapies for orthopedic surgeons and patients through its comprehensive minimally invasive meniscal repair platform. It includes the only FDA-approved collagen meniscus implant (CMI®) on the market. Ivy’s history and sole focus on advancing the... Read More »

Danaher Doubles Down on Blood Diagnostics

by | Sep 9, 2016 3:08 pm | Biotechnology

Danaher Corporation (NASDAQ: DHR) has set a new direction for itself, after spinning off its Test & Measurement segment, Industrial Technologies segment and its Retail/Commercial Petroleum platform into Fortive Corporation (NYSE: FTV) on July 2. Post-separation, the company is positioned as a global science and technology  innovator with more than 20 operating companies in the health care, environmental and industrial industries. In September, Danaher announced its acquisition of Cepheid (NASDAQ: CPHD ) for $3.9 billion, or $53.00 per share. The consideration represents approximately a 54% percent premium to Cepheid’s common stock over the closing price of $34.42 on September 2,... Read More »